Otulfi 90 mg (Ustekinumab SOLUTION) 90 MG

OTULFI 90 MG is a subcutaneous solution containing ustekinumab, used for managing moderate to severe plaque psoriasis. This biologic medication helps reduce inflammation and improve skin condition.

Strength

90 MG

Manufacturer / TM Owner

FRESENIUS KABI CANADA LTD

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

OTULFI 90 MG is primarily used for the treatment of moderate to severe plaque psoriasis in adults. This medication works by targeting specific proteins in the body to reduce inflammation and slow down the overproduction of skin cells. People often ask, 'What is OTULFI 90 MG used for?' It is designed to help manage symptoms and improve the quality of life for those with chronic skin conditions.

Side Effects

Common effects of OTULFI 90 MG may include redness, itching, or swelling at the injection site. Some users might experience headaches, fatigue, or mild upper respiratory infections. These effects are generally mild and temporary, but it's important to monitor any persistent or severe reactions.

Precautions & Warnings

OTULFI 90 MG should be stored as directed and used under medical supervision. It is important to inform healthcare providers about any allergies or existing medical conditions before starting treatment. Proper handling and administration techniques should be followed to minimize risks.

Avoid Interactions

OTULFI 90 MG may interact with other medications, including immunosuppressants and live vaccines. Alcohol and certain CYP inhibitors might also affect its efficacy. Always consult a healthcare provider before combining OTULFI 90 MG with other treatments.

Frequently Asked Questions

OTULFI 90 MG is used to treat moderate to severe plaque psoriasis by reducing inflammation and skin cell overproduction.

OTULFI 90 MG is administered subcutaneously, typically by a healthcare professional or as directed.

Common side effects include redness, itching, or swelling at the injection site, headaches, fatigue, and mild upper respiratory infections.

OTULFI 90 MG may interact with other medications, so it's important to consult a healthcare provider before combining it with other treatments.

OTULFI 90 MG should be stored according to the manufacturer's instructions, typically in a refrigerator between 2°C to 8°C.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.